STAT3 as a therapeutic target in head and neck cancer

Expert Opinion on Biological Therapy

Volumn 6, Issue 3, 2006, Pages 231-241

  Leeman, Rebecca J ^a   Lui, Vivian Wai Yan ^a   Grandis, Jennifer Rubin ^a  

^a University of Pittsburgh School of Medicine   (United States)

Author keywords

Head and neck cancer; STAT3 inhibitors; STAT3 targeted therapy

Indexed keywords

APTAMER; BEXAROTENE; CUCURBITACIN GLYCOSIDE; CYTOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; JSI 124; OLIGONUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROTEIN TYROSINE KINASE; RETINOID X RECEPTOR ALPHA; STAT3 PROTEIN; SULINDAC; TRANSFORMING GROWTH FACTOR ALPHA;

APOPTOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; DIMERIZATION; DRUG TARGETING; ENZYME INHIBITION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANIMALS; GENE TARGETING; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 33644773438     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.3.231     Document Type: Review

References (125)

1. STAHL N, FARRUGGELLA TJ, BOULTON TG, ZHONG Z, DARNELL JE, YANCOPOULOS GD: Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science (1995) 267:1349-1353.
2. DARNELL J, KERR IM, STARK GR: Jak-STAT pathway and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 264:1415-1421.
3. SILVENNOINEN O, SCHINDLER C, SCHLESSINGER J, LEVY DE: Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science (1993) 261:1736-1739.
4. CHEN E, GADINA M, CHEN M, O'SHEA JJ: Advances in cytokine signaling: the role of Jaks and STATs. Transplant. Proc. (1999) 31:1482-1487.
5. BRISCOE J, KOHLHUBER F, MULLER M: JAKs and STATs branch out. Trends Cell Biol. (1996) 6:336-340.
6. IHLE JN, KERR IM: Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. (1995) 11(2):69-74.
7. SCHINDLER C, SHUAI K, PREZIOSO VR, DARNELL JE: Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science (1992) 257:809-813.
8. GREENLUND AC, FARRAR MA, VIVIAN BL, SCHREIBER RD: Ligand-induced interferon gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J. (1994) 13(7):1591-1600.
9. QUELLE FW, THIERFELDER W, WITTHUHN BA, TANG B, COHEN S, IHLE JN: Phosphorylation and activation of the DNA binding activity of purified Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor receptor. J. Biol. Chem. (1995) 35:20775-20780.
10. VIGNAIS M, SADOWSKI HB, WATLING D, ROGERS NC, GILMAN M: Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol. Cell. Biol. (1996) 16(4):1759-1769.
11. RUFF-JAMISON S, ZHONG Z, WEN Z, CHEN K, DARNELL JE, COHEN S: Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J. Biol. Chem. (1994) 269(35):21933-21935.
12. DARNELL JE: STATs and gene regulation. Science (1997) 277:1630-1635.
13. SHAO H, CHENG HY, COOK RG, TWEARDY DJ: Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. (2003) 63(14):3923-3930.
14. DANIAL NN, ALESSANDRA P, ROTHMAN PB: Jak-STAT signaling induced by the v-abl oncogene. Science (1995) 269:1875-1877.
15. TURKSON J, BOWMAN T, GARCIA R, CALDENHOVEN E, DE GROOT RP, JOVE R: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. (1998) 18(5):2545-2552.
16. SHUAI K, SCHINDLER C, PREZIOSO VR, DARNELL JE: Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91-kD DNA binding protein. Science (1992) 258(5089):1808-1812.
17. LIU L, MCBRIDE KM, REICH NC: STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3. Proc. Natl. Acad. Sci. USA (2005) 102(23):8150-8155.
18. KOMYOD W, BAUER U, HEINRICH PC, HAAN S, BEHRMANN I: Are STATS arginine-methylated? J. Biol. Chem. (2005) 280(23):21700-21705.
19. MOWEN K, TANG J, ZHU W et al.: Arginine methylation of STAT1 modulates IFNα/β-induced transcription. Cell (2001) 104:731-741.
20. YUAN Z, GUAN Y, CHATTERJEE D, CHIN YE: Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science (2005) 307:269-273.
21. ZHONG Z, WEN Z, DARNELL JE: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 264:95-98.
22. DECKER T, LEW DJ, MIRKOVITCH J, DARNELL JE: Cytoplasmic activation of GAF, an IFN-γ-regulated DNA-binding factor. EMBO J. (1991) 10(4):927-932.
23. AARONSON DS, HORVATH CM: A road map for those who don't know JAK-STAT Science (2002) 296:1653-1655.
24. BUGNO M, GRAEVE L, GATSIOS P et al.: Identification of the interleukin-6/oncostatin M response element in the rat tissue inhibitor of metalloproteinase-1 (TIMP-1) promoter. Nucl. Acid Res. (1995) 23(24):5041-5047.
25. SCHAEFER TS, SANDERS LK, NATHANS D: Cooperative transcriptional activity of Jun and Stat3β, a short form of Stat3. Proc. Natl. Acad. Sci. USA (1995) 92:9097-9101.
26. CALO V, MIGLIAVACCA M, BAZAN V et al.: STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. (2003) 197:157-168.
27. BROMBERG J, HORVATH CM, BESSER D, LATHEM WW, DARNELL JE: Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. (1998) 18(5):2553-2558.
28. BROMBERG JF, WRZESZCZYNSKA MH, DEVGAN G et al.: Stat3 as an oncogene. Cell. (1999) 98:295-303. An original work revealing the oncogenic activity of STAT3.
29. BOWMAN T, GARCIA R, TURKSON J, JOVE R: STATs in oncogenesis. Oncogene (2000) 19:2474-2488.
30. GRANDIS JR, DRENNING SD, CHAKRABORTY A et al.: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest. (1998) 102(7):1385-1392.
31. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM et al.: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10:105-115.
32. NIU G, HELLER R, CATLETT-FALCONE R et al.: Gene therapy with dominant-negative Stat3 supresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. (1999) 59:5059-5063.
33. GARCIA R, BOWMAN T, NIU G et al.: Constitutive activation of Stat3 by the Src and Jak tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 20:2499-2513.
34. NIU G, BOWMAN T, HUANG M et al.: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 21:7001-7010.
35. TUMANG J, HSIA CY, TIAN W, BROMBERG JF, LIOU H: IL-6 rescues the hyporesponsiveness of c-Rel deficient B cells independent of Bcl-xL, Mcl-1, and Bcl-2. Cell. Immunol. (2002) 217:47-57.
36. DAUER DJ, FERRARO B, SONG L et al.: Stat3 regulates genes common to both wound healing and cancer. Oncogene (2005) 21(21):3397-3408. A good resource for STAT3 target genes.
37. YANG J, CHATTERJEE-KISHORE M, STAUGAITIS SM et al.: Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. (2005) 65(3):939-947. An interesting study on the role of unphosphorylated STAT3.
38. THOMAS SM, GRANDIS JR: Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat. Rev. (2004) 30:255-268.
39. SUZUKI A, HANADA T, MITSUYAMA K et al.: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. (2001) 193(4):471-481
40. CHUNG CD, LIAO J, LIU B et al.: Specific inhibition of Stat3 signal transduction by PIAS3. Science (1997) 278(5344):1803-1805.
41. LUFEI C, MA J, HUANG G et al.: GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J. (2003) 22(6):1325-1335.
42. FORD AC, GRANDIS JR: Targeting epidermal growth factor receptor in head and neck cancer. Head Neck (2003) 25:67-73.
43. JAMES C, UGO V, CASADEVALL N, CONSTANTINESCU SN, VAINCHENKER W: A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol. Med. (2005) 11(12):546-554.
44. JAMES C, UGO V, LE COUEDIC J et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 434:1144-1148.
45. BOWMAN T, BROOME MA, SINIBALDI D et al.: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA (2001) 98(13):7319-7324.
46. YU H, JOVE R: The STATs of cancer- new molecular targets come of age. Nature Rev. (2004) 4:97-105. A thorough review of STATs.
47. STARR R, HILTON DJ: Negative regulation of the JAK/STAT pathway. BioEssays (1999) 21:47-52.
48. YOSHIKAWA H, MATSUBARA K, QIAN G et al.: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. (2001) 28:29-35.
49. GALM O, YOSHIKAWA H, ESTELLER M, OSIEKA R, HERMAN J: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2003) 101(7):2784-2788.
50. KOMAZAKI T, NAGAI H, EMI M et al.: Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn. J. Clin. Oncol. (2004) 34(4):191-194.
51. NAGAI H, NAKA T, TERADA Y et al.: Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/ STAT inhibitor, in human hepatoblastomas. J. Hum. Genet. (2003) 48:65-69.
52. HE B, YOU L, UEMATSU K et al.: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. USA (2003) 100(24):14133-14138.
53. ZHANG Q, RAGHUNATH PN, XUE L et al.: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. (2002) 168:466-474.
54. OKA T, OUCHIDA M, KOYAMA M et al.: Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. (2002) 62(22):6390-6394.
55. CHIM C, FUNG T, CHEUNG W, LIANG R, KWONG Y: SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood (2004) 103(12):4630-4635.
56. ENDO TA, MASUHARA M, YOKOUCHI M et al.: A new protein containing an SH2 domain that inhibits JAK kinases. Nature (1997) 387:921-924.
57. NAKA T, FUJIMOTO M, KISHIMOTO T: Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem. Sci. (1999) 24:394-398.
58. NAKA T, NARAZAKI M, HIRATA M et al.: Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 387:924-929.
59. FLOWERS L, SUBRAMANIAM PS, JOHNSON HM: A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene (2005) 24:2114-2120.
60. LARSEN L, ROPKE C: Suppressors of cytokine signalling: SOCS. APMIS (2002) 110(12):833-844.
61. SHUAI K: Modulation of STAT signaling by STAT-interacting proteins. Oncogene (2000) 19:2638-2644.
62. DAVID M, CHEN HE, GOELZ S, LARNER AC, NEEL BG: Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. (1995) 15(12):7050-7058.
63. JIAO H, BERRADA K, YANG W, TABRIZI M, PLATANIAS LC, YI T: Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol. Cell. Biol. (1996) 16(12):6985-6992.
64. LEVY DE, DARNELL JE JR: STATs: transcriptional control and biological impact. Nature Rev. (2002) 3:651-662.
65. COLLUM RG, BRUTSAERT S, LEE G, SCHINDLER C: A Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc. Natl. Acad. Sci. USA (2000) 97(18):10120-10125.
66. ZHANG J, YANG J, ROY SK et al.: The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc. Natl. Acad. Sci. USA (2003) 100(16):9342-9347.
67. GRANDIS JR, DRENNING SD, ZENG Q et al.: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA (2000) 97(8):4227-4232.
68. KIJIMA T, NIWA H, STEINMAN RA et al.: STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell. Growth Diff. (2002) 13:355-362.
69. SRIURANPONG V, PARK JI, AMORNPHIMOLTHAM P, PATEL V, NELKIN BD, GUTKIND JS: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. (2003) 63(11):2948-2956.
70. GRANDIS JR, ZENG Q, DRENNING SD: Epidermal growth factor receptor-mediated Stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope (2000) 110:868-874.
71. XI S, ZHANG Q, DYER KF et al.: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem. (2003) 278:31574-31583.
72. NAGPAL JK, MISHRA R, DAS BR: Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer (2002) 94:2393-2400.
73. ARANY I, CHEN S, MEGYESI JK et al.: Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett. (2003) 199:83-89.
74. MASUDA M, SUZUI M, YASUMATU R et al.: Constitutive activation of signal transducers and activators of transcription 3 correlates with Cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. (2002) 62:3351-3355.
75. BLASKOVICH MA, SUN J, CANTOR A, TURKSON J, JOVE R, SEBTI SM: Discovery of JSI-124 (curcurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. (2003) 63:1270-1279.
76. BERG T, COHEN SB, DESHARNAIS J et al.: Small-molecule antagonists of myc/ max dimerization inhibit myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA (2002) 99(6):3830-3835.
77. TURKSON J, KIM JS, ZHANG S et al.: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. (2004) 3(3):261-269.
78. TURKSON J, RYAN D, KIM JS et al.: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. (2001) 276(48):45443-45455.
79. REN Z, CABELL LA, SCHAEFER TS, MCMURRAY JS: Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett. (2003) 13:633-636.
80. BUERGER C, GRONER B: Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling. J. Cancer Res. Clin. Oncol. (2003) 129:669-675.
81. BUERGER C, NAGEL-WOLFRUM K, KUNZ C et al.: Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J. Biol. Chem. (2003) 278(39):37610-37621.
82. NAGEL-WOLFRUM K, BUERGER C, WITTIG I, BUTZ K, HOPPE-SEYLER F, GRONER B: The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol. Cancer Res. (2004) 2:170-182.
83. BATES P, KAHLON JB, THOMAS SD, TRENT JO, MILLER DM: Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem. (1999) 10(274):26369-26377.
84. JING N, LI Y, XU X et al.: Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol. (2003) 22(11):685-696.
85. JING N, LI Y, XIONG W, SHA W, JING L, TWEARDY DJ: G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. (2004) 64:6603-6609.
86. JING N, TWEARDY DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs (2005) 16(6):601-607.
87. JING N, SHA W, LI Y, XIONG W, TWEARDY DJ: Rational drug design of G-quartet DNA as anti-cancer agents. Curr. Pharm. Des. (2005) 11(22):2841-2854.
88. COPPELLI F, GRANDIS JR: Oligonucleotides as anticancer agents: from the benchside to clinic and beyond. Curr. Pharm. Des. (2005) 11(22):2825-2840.
89. GAO LE XU DQ, WEN LJ, ZHANG XY, SHAO YT, ZHAO XJ: Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol. Sin. (2005) 26(3):377-383.
90. KONNIKOVA L. KOTECKI M, KRUGER MM, COCHRAN BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer (2003) 3:23.
91. KAWAMURA I, MORISHITA R, TSUJIMOTO S et al.: Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther. (2001) 8(12):905-912.
92. LEONG PL, ANDREWS GA, JOHNSON DE et al.: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA (2003) 100(7):4138-4143.
93. XI S, GOODING WE, GRANDIS JR: In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene (2005) 24:970-979.
94. CHAN KS, SANO S, KIGUCHI K et al.: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. (2004) 114(5):720-728. An interesting study revealing the role of STAT3 in epithelial carcinogenesis in animal models.
95. PARK Y, NESTEROVA M, AGRAWAL S, CHO-CHUNG YS: Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. J. Biol. Chem. (1999) 274:1573-1580.
96. BARTON B, MURPHY TF, SHU P, HUANG HF, MEYENHOFEN M, BARTON A: Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol. Cancer Ther. (2004) 3(10):1183-1191.
97. LANGO M, WENTZEL AL, SONG JI et al.: Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor α/epidermal growth factor receptor autocrine signaling in head snd neck squamous carcinoma cells. Clin. Cancer Res. (2003) 9:4205-4213.
98. SONG JI, LANGO MN, HWANG JD et al.: Abrogation of transforming growth factor-α/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. J. Cancer Res. (2001) 61:5919-5925.
99. NIKITAKIS NG, HAMBURGER AW, SAUK JJ: The nonsteroidal anti-inflammatory drug Sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res. (2002) 62:1004-1007.
100. 2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes down-regulation of Stat3 in human oral SCCa cells. Br. J. Cancer (2002) 87:1396-1403.
101. SINIBALDI D, WHARTON W, TURKSON J, BOWMAN T, PLEDGER WJ, JOVE R: Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene (2000) 19(48):5419-5427.
102. MATSUMURA I, KITAMURA T, WAKAO H et al.: Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. FMBO J. (1999) 18(5):1367-1377.
103. AMIN HM, MCDONNELL TJ, MA Y et al.: Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene (2004) 23(32):5426-5434.
104. KIUCHI N, NAKAJIMA K, ICHIBA M et al.: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med. (1999) 189(1):63-73.
105. LORD JD, MCINTOSH BC, GREENBERG PD, NELSON BH: The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. (2000) 164(5):2533-2541.
106. NARIMATSU M, NAKAJIMA K, ICHIBA M, HIRANO T: Association of Stat3-dependent transcriptional activation of p19INK4D with IL-6-induced growth arrest. Biochem. Biophys. Res. Commun. (1997) 238(3):764-768.
107. BELLIDO T, O'BRIEN CA, ROBERSON PK, MANOLAGAS SC: Transcriptional activation of the p21 (WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J. Biol. Chem. (1998) 273(33):21137-21144.
108. TAKAHASHI S, HARIGAE H, KAKU M, SASAKI T, LICHT JD: Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5. Biochem. Biophys. Res. Commun. (2004) 316(1):85-92.
109. SHIROGANE T, FUKADA T, MULLER JM, SHIMA DT, HIBI M, HIRANO T: Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity (1999) 11(6):709-719.
110. MUI AL, WAKAO H, KINOSHITA T, KITAMURA T, MIYAJIMA A: Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. (1996) 15(10):2425-2433.
111. DE KONING JP, SOEDE-BOBOK AA, WARD AC et al.: STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene (2000) 19(29):3290-3298.
112. KLAUSEN P, PEDERSEN L, JURLANDER J, BAUMANN H: Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene (2000) 19(32):3675-3683.
113. AOKI Y, FELDMAN GM, TOSATO G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood (2003) 101(4):1535-1542.
114. EPLING-BURNETTE PK, LIU JH, CATLETT-FALCONE R et al.: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. (2001) 107(3):351-362.
115. ORITANI K, TOMIYAMA Y, KINCADE PW et al.: Both Stat3-activation and Stat3-independent BCL2 downregulation are important for interleukin-6-induced apoptosis of 1A9-M cells. Blood (1999) 93(4):1346-1354.
116. MOUCADEL V, CONSTANTINESCU SN: Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. J. Biol. Chem. (2005) 280(14):13364-13373.
117. NIU G, WRIGHT KL, HUANG M et al.: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 21(13):2000-2008.
118. XIE TX, WEI D, LIU M et al.: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene (2004) 23(20):3550-3560.
119. DECHOW TN, PEDRANZINI L, LEITCH A et al.: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. USA (2004) 101(29):10602-10607.
120. BRENDER C, NIELSEN M, KALTOFT K et al.: STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood (2001) 97(4):1056-1062.
121. SCHICK N, OAKELEY EJ, HYNES NE, BADACHE A: TEL/ETV6 is a signal transducer and activator of transcription 3 (Stat3)-induced repressor of Stat3 activity. J. Biol. Chem. (2004) 279(37):38787-38796.
122. ZHANG X, DARNELL JR JR: Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene. J. Biol. Chem. (2001) 276(36):33576-33581.
123. WANG Y, RIPPERGER J, FEY GH et al.: Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells. Hepatology (1999) 30(3):682-697.
124. KOJIMA H, NAKAJIMA K, HIRANO T: IL-6-inducible complexes on an IL-6 response element of the junB promoter contain Stat3 and 36 kDa CRE-like site binding protein(s). Oncogene (1996) 12(3):547-554.
125. LAI R, RASSIDAKIS GZ, MEDEIROS LJ et al.: Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Am. J. Pathol. (2004) 164(6):2251-2258.